Hillsdale Investment Management Inc. Sells 33,520 Shares of Guardant Health, Inc. $GH

Hillsdale Investment Management Inc. reduced its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 21.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 122,380 shares of the company’s stock after selling 33,520 shares during the period. Hillsdale Investment Management Inc.’s holdings in Guardant Health were worth $12,500,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in GH. V Square Quantitative Management LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health during the 4th quarter worth approximately $31,000. Elyxium Wealth LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $35,000. Finally, First Pacific Financial bought a new position in shares of Guardant Health during the 4th quarter worth approximately $43,000. 92.60% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Amirali Talasaz sold 210,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total value of $1,250,800.00. Following the completion of the sale, the insider directly owned 35,950 shares of the company’s stock, valued at approximately $4,496,626. The trade was a 21.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 332,244 shares of company stock worth $36,156,026 in the last quarter. 5.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GH. Barclays raised their price target on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Stifel Nicolaus raised their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. BTIG Research set a $160.00 price target on shares of Guardant Health and gave the stock a “buy” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. increased their price objective on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $129.79.

Guardant Health Trading Down 2.6%

NASDAQ GH opened at $129.69 on Friday. The company has a market cap of $17.20 billion, a PE ratio of -38.26 and a beta of 1.48. Guardant Health, Inc. has a 12 month low of $38.03 and a 12 month high of $133.97. The stock has a 50 day moving average of $95.08 and a 200-day moving average of $99.94.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.